The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND. Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients. AIMS. The aim of this study is to elucidate the effectiveness of liraglutide in NAFLD patients with type 2 diabetes mellitus (T2DM) compared to sitagliptin and pioglitazone. METHODS. We retrospectively enrolled 82 Japanese NAFLD patients with T2DM and divided into three groups (liraglutide: N = 26, sitagliptin; N = 36, pioglitazone; N = 20). We compared the baseline characteristics, changes of laboratory data and body weight. RESULTS. At the end of follow-up, ALT, fast blood glucose, and HbA1c level significantly improved among the three groups. AST to platelet ratio significantly decreased in liraglutide group and pioglitazone group. The body weight significantly decreased in liraglutide group (81.8 kg to 78.0 kg, P < 0.01). On the other hands, the body weight significantly increased in pioglitazone group and did not change in sitagliptin group. Multivariate regression analysis indicated that administration of liraglutide as an independent factor of body weight reduction for more than 5% (OR 9.04; 95% CI 1.12-73.1, P = 0.04). CONCLUSIONS. Administration of liraglutide improved T2DM but also improvement of liver inflammation, alteration of liver fibrosis, and reduction of body weight.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a retrospective study, liraglutide and pioglitazone, but not sitagliptin, decreased liver fibrosis index APRI (calculated as the aspartate aminotransferase (AST) to platelet count ratio), and the improvement was associated with weight loss and a marked reduction in AST and ALT levels [149].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [149]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elm, E. V., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · BMJ · doi:10.1136/bmj.39335.541782.ad · Cited by 10,766
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“Since in a randomized controlled trial intended for NAFLD patients, pioglitazone demonstrated alteration of liver inflammation but did not affect on improvement of liver fibrosis [6].”
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · cited 2×
“Weight reduction via lifestyle intervention is generally recommended as an initial step in the management of NAFLD [27], and its effectiveness was proven in a randomized controlled trial [8].”
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 2×
“Particularly, trials of glucose lowering agents such as metformin and pioglitazone have yielded promising results [18, 26].”
The prevalence and etiology of elevated aminotransferase levels in the United States
Clark, J. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00265-x · Cited by 1,360
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“In addition, GLP-1 prolongs gastric emptying and induces satiety, leading to decreased energy intake and body weight [10, 11].”
Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., & Bacon, B. R. (2003) · Hepatology · doi:10.1002/hep.1840380427 · Cited by 751
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss
Dixon, J. B., Bhathal, P. S., Hughes, N. R., & O'Brien, P. E. (2004) · Hepatology · doi:10.1002/hep.20251 · Cited by 727 · cited 1×
“The Scientific World Journal Volume 2012, Article ID 496453, 8 pages doi:10.1100/2012/496453 The cientificWorldJOURNAL”
InfluentialMiyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726
Bugianesi, E., Gentilcore, E., Manini, R., Natale, S., Vanni, E., Villanova, N., David, E., Rizzetto, M., & Marchesini, G. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41583.x · Cited by 691
Verdich, C., Flint, A., Gutzwiller, J.-P., Näslund, E., Beglinger, C., Hellström, P. M., Long, S. J., Morgan, L. M., Holst, J. J., & Astrup, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7877 · Cited by 600
Gupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 1×
“These small structural differences prolong the half-life of GLP-1 to 13 hours, making it possible for once daily administration [12].”
Nonalcoholic fatty liver disease: A review of current understanding and future impact
Charlton, M. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00440-9 · Cited by 350
Verdich, C. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.9.4382 · Cited by 336
Insulin Resistance, the Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease
Angelico, F., Del Ben, M., Conti, R., Francioso, S., Feole, K., Fiorello, S., Cavallo, M. G., Zalunardo, B., Lirussi, F., Alessandri, C., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1024 · Cited by 284
Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?
McIntosh, C. H. S., Demuth, H.-U., Pospisilik, J. A., & Pederson, R. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.001 · Cited by 192
Is weight reduction an effective therapy for nonalcoholic fatty liver?
Wang, R. T., Koretz, R. L., & Yee, H. F. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00449-2 · Cited by 154
Firneisz, G., Varga, T., Lengyel, G., Fehér, J., Ghyczy, D., Wichmann, B., Selmeci, L., Tulassay, Z., Rácz, K., & Somogyi, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012226 · Cited by 121
Samson, S. L., Sathyanarayana, P., Jogi, M., Gonzalez, E. V., Gutierrez, A., Krishnamurthy, R., Muthupillai, R., Chan, L., & Bajaj, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2317-z · Cited by 110
Balas, B., Belfort, R., Harrison, S. A., Darland, C., Finch, J., Schenker, S., Gastaldelli, A., & Cusi, K. J. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.04.013 · Cited by 93
Research works printed but not linked: 2
- 10.1111/j.1572-0241.2003.07486.x · doi:10.1111/j.1572-0241.2003.07486.x · Paper page
- 10.1053/jhep.2003.50420 · doi:10.1053/jhep.2003.50420 · Paper page
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Khan, R. S., Bril, F., Cusi, K., & Newsome, P. N. (2019) · Hepatology · doi:10.1002/hep.30429 · Cited by 542
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Muzurović, E., Mikhailidis, D. P., & Mantzoros, C. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154770 · Cited by 336
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
Metadata
- Authors
- Ohki, T., Isogawa, A., Iwamoto, M., Ohsugi, M., Yoshida, H., Toda, N., Tagawa, K., Omata, M., & Koike, K.
- Affiliations
- Mitsui Memorial Hospital (JP)
- The University of Tokyo (JP)
- Yamanashi Prefectural Hospital Organization (JP)
- Corresponding author
- Yoshida, Haruhiko
- Venue
- The Scientific World Journal
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-8
- ISSN
- 1537-744X (ISSN-L)
- PMC
- PMC3425807
- OpenAlex
- W2113064802
- Cited by
- 139
- References
- 29
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 14 · 2023: 11 · 2022: 10 · 2021: 15 · 2020: 15 · 2019: 11 · 2018: 11 · 2017: 6 · 2016: 14 · 2015: 10 · 2014: 9 · 2013: 3
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- The Scientific World JOURNAL (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- liraglutide, non-alcoholic fatty liver disease, type 2 diabetes, sitagliptin, pioglitazone, weight loss, liver inflammation, ALT, HbA1c, glycemic control, GLP-1 receptor agonists
- MeSH terms
- Sitagliptin Phosphate, Liraglutide, Pioglitazone, Adult, Alanine Transaminase, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Drug Evaluation, Drug Therapy, Combination, Fatty Liver, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Inflammation, Liver Cirrhosis, Male, Middle Aged, Platelet Count, Pyrazines, Retrospective Studies, Triazoles, Comorbidity, Multivariate Analysis, Logistic Models, Odds Ratio, Treatment Outcome, Thiazolidinediones, Glucagon-Like Peptide 1, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.